Happy Monday! Stocks are hitting all-time highs, yet whispers of caution are growing louder among Wall Street’s top experts. Read on to learn what’s fueling both optimism and concern, and what it could mean for your investments going forward.

Also, President Trump’s rare visit to the Federal Reserve sent more than just a political message — it signaled a brewing clash over the future of U.S. economic policy. Discover what’s at stake, and why economists are sounding the alarm.

Plus, if you’re looking for a biotech company progressing toward a breakthrough in treating Alzheimer’s, check out today’s sponsor.

In Today's Edition

• MARKET RECAP

• MARKET HEATMAP

• FIVE ZINGERS

• MARKET HISTORY

• ONE FOR THE ROAD

Is A Stock Market Crash Coming? Analysts Sound The Alarm With Indexes At Record Highs

It was another record week on Wall Street with indexes hitting new all-time highs.

But behind the celebration, some of the biggest minds on Wall Street are worried about what comes next. From Goldman Sachs and Bank of America to JPMorgan and Ed Yardeni, warnings are growing louder that we may be in the late stages of a market bubble similar to those of 1999 and 2021.

Speculative trading is spiking, AI valuations are soaring past dot-com era levels and retail enthusiasm is surging — fueled by relaxed regulations and a flood of liquidity.

Call option activity is at its highest point since 2021, unprofitable stocks are rallying and SPACs are back with a vengeance. Meanwhile, nearly 40% of the S&P 500’s value is now concentrated in just 10 tech-heavy names. To some, it’s the sign of a strong bull market. To others, it’s a familiar setup for a painful correction.

Read the full story to see what Wall Street’s top minds are warning about, and what it could mean for your portfolio in the weeks and months ahead.

Cognition Therapeutics Inc. (NASDAQ: CGTX), a clinical-stage company developing drugs to treat neurodegenerative disorders, held an end-of-phase 2 meeting with the U.S. FDA that could spur a phase 3 trial of its candidate zervimesine (CT1812) to treat Alzheimer’s.

The objective of the meeting was to review results from the phase 2 study and discuss next steps to eventually support a new drug application (NDA) for zervimesine as a treatment for Alzheimer’s disease.

“We believe we have a path forward for the development of zervimesine in the treatment of Alzheimer’s disease,” said Lisa Ricciardi, president and CEO of Cognition. “We look forward to reviewing the FDA’s formal minutes in August to confirm our path forward.”

To learn more about Cognition and zervimesine, click here.

This is a paid ad. Please see 17b disclosure here for more information.

Last Week: U.S. indexes ended the week higher Friday, with the S&P 500 and Nasdaq both posting fresh record highs as strong earnings and easing trade tensions boosted investor confidence. The S&P 500 notched its fifth straight record close and 14th of the year, while the Nasdaq marked its 15th, with both indexes also hitting new all-time intraday highs. The 10-year Treasury yield fell to 4.38% and oil dropped as well to settle at a three-week low. Durable goods orders dropped 9.3% in June, less than forecast, following a sharp rise in May, suggesting continued strength in manufacturing. The earnings season has remained strong, with 82% of S&P 500 companies that have reported so far beating estimates. This has lifted second-quarter growth to 5.4% vs. expectations of 3.8% just a few weeks ago.

On Our Radar: Analysts will be monitoring several reports Tuesday morning with retail inventories, wholesale inventories and trade balance in goods being released before the market open. On the earnings front, Boeing (BA), UnitedHealth (UNH), Royal Caribbean (RCL) and UPS (UPS) will headline a slate of major earnings reports that will be released before the market opens on Tuesday.

Shares of Deckers and Newmont were soaring on Friday, while Tesla rebounded with some nice gains after nearly falling 10% on Thursday. But those weren’t the only big movers of the day…

Discover how the market is moving with our interactive heatmap — filter by market cap and zoom in for deeper insights. Click any box to explore specific sectors or assets in detail.

Join us on November 10, 2025, in New York City for a transformative experience that blends cutting-edge financial technology insights with unparalleled networking opportunities. This event is designed to showcase the latest advancements in fintech, celebrate industry achievements and foster connections that drive the future of finance. Join us for a powerhouse event designed to connect visionary leaders, ignite groundbreaking deals and celebrate the brightest stars in the financial technology industry.

On This Day In 1989…

Bristol‑Myers and Squibb announced a $12 billion merger, forming Bristol‑Myers Squibb, which at the time became the second-largest pharmaceutical company in the world. The merger combined Squibb’s prescription drugs with Bristol‑Myers’ consumer products and research strength. This transformed the company into a global powerhouse with robust R&D, diversified revenue streams and blockbuster launches throughout the 1990s. Today, the company still remains a major player and has a market cap of nearly $100 billion.

QUOTE OF THE DAY

“Price is what you pay. Value is what you get.”

— Warren Buffett

Trump's Rare Fed Visit Sparks Talks Of A $7 Trillion Problem

President Trump’s rare and very public visit to the Federal Reserve — becoming just the fourth sitting President to do so — wasn’t just a photo-op, but a preview of the next big battle over America’s economic future.

While the visit was billed as a tour of the central bank’s renovation, it quickly became clear there was more at stake than bricks and budgets. A sharp, on-camera clash with Fed Chair Jerome Powell drew headlines, but behind the tension lies a far deeper concern: the U.S. government’s $7.1 trillion deficit and the $1 trillion it now pays in annual interest.

The math is becoming impossible to ignore, and markets are beginning to sense it. With Trump eyeing aggressive fiscal expansion and publicly pressuring the Fed to lower rates, economists are warning of a potential shift toward policies that could shake the foundation of U.S. monetary strategy — including the once-unthinkable idea of yield curve control.

Read on for more insights and how it could impact your portfolio.

BEFORE YOU GO

Were you forwarded this email? Click here to subscribe.

And be sure to check out our other newsletters:

Future Finance: Where fintech, crypto and the future of finance collide. Future Finance is a perfect lunch read packed with quick bites for industry enthusiasts. Subscribe here.

Advisor: Tailor-made for Financial Advisors, this weekly newsletter has industry-specific insights, analysis and news. Subscribe here.

Tech Trends: Get the inside scoop on AI, the hottest gadgets and mind-blowing tech trends. Subscribe here.